Publicité
La bourse ferme dans 2 h 56 min

  • CAC 40

    8 002,55
    +21,04 (+0,26 %)
     

  • Euro Stoxx 50

    4 926,81
    +12,68 (+0,26 %)
     

  • Dow Jones

    37 753,31
    -45,66 (-0,12 %)
     

  • EUR/USD

    1,0666
    -0,0009 (-0,09 %)
     

  • Gold future

    2 398,00
    +9,60 (+0,40 %)
     

  • Bitcoin EUR

    57 999,09
    -627,08 (-1,07 %)
     

  • CMC Crypto 200

    885,54
    0,00 (0,00 %)
     

  • Pétrole WTI

    82,31
    -0,38 (-0,46 %)
     

  • DAX

    17 758,27
    -11,75 (-0,07 %)
     

  • FTSE 100

    7 861,24
    +13,25 (+0,17 %)
     

  • Nasdaq

    15 683,37
    -181,88 (-1,15 %)
     

  • S&P 500

    5 022,21
    -29,20 (-0,58 %)
     

  • Nikkei 225

    38 079,70
    +117,90 (+0,31 %)
     

  • HANG SENG

    16 385,87
    +134,03 (+0,82 %)
     

  • GBP/USD

    1,2452
    -0,0005 (-0,04 %)
     

Why Verastem Stock Sank Today

Evan Niu, CFA, The Motley Fool
·2 min de lecture
Why Verastem Stock Sank Today

Shares of Verastem (NASDAQ: VSTM) sank Wednesday, trading down by 10% as of 2:30 p.m. EST after the company announced that Chief Medical Officer Dr. Frank Neumann is departing. The surprise news comes just two weeks after Neumann joined Verastem from Bluebird Bio, where he had served as head of oncology clinical research. Neumann, an industry veteran, was expected to be instrumental in Verastem's development of VS-6766 and defactinib, a pair of oral small-molecule inhibitors that are currently undergoing clinical trials as potential cancer treatments.

Continuer la lecture